BIO-B - Bio-Rad Laboratories, Inc.

NYSE - NYSE Delayed Price. Currency in USD
306.49
0.00 (0.00%)
At close: 9:41AM EDT
Stock chart is not supported by your current browser
Previous Close306.49
Open306.49
Bid294.45 x 800
Ask297.09 x 800
Day's Range306.49 - 306.49
52 Week Range220.93 - 324.25
Volume4
Avg. Volume140
Market Cap8.828B
Beta (3Y Monthly)1.38
PE Ratio (TTM)25.33
EPS (TTM)12.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire6 hours ago

    Bio-Rad to Participate in the Bank of America Merrill Lynch Health Care Conference 2019 in May

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 on May 14, at 10:40 AM Pacific Time, at the Encore Hotel, Las Vegas, Nevada.

  • Business Wireyesterday

    Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April 22, 2019. “We are pleased to have Andrew join Bio-Rad and believe his strong background in global management and leadership spanning the life science, diagnostics, and pharmaceutical industries coupled with his technical expertise will be an invaluable asset to Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO. Dr. Last brings over 30 years of global management experience to Bio-Rad.

  • Is Bio-Rad Laboratories, Inc. (BIO) A Good Stock To Buy?
    Insider Monkey3 days ago

    Is Bio-Rad Laboratories, Inc. (BIO) A Good Stock To Buy?

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Business Wire8 days ago

    Bio-Rad to Report First-Quarter 2019 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.

  • FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year
    American City Business Journals14 days ago

    FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year

    A small handful of the Bay Area's largest tech employers, including Facebook, Palo Alto Networks, Splunk and Broadcom, pay their median employee above $200,000 per year.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

    Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BIO are favorable with net inflows of $183.01 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News
    Investor's Business Daily15 days ago

    Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News

    Stock futures: Zogenix plunged early Tuesday on FDA news, while GW Pharma stock rose and PhaseBio stock soared. Bio-Rad won an FDA approval, but shares were quiet near a buy point.

  • Business Wire15 days ago

    Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S.

  • Business Wire21 days ago

    Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019. Mr. Daskal comes to Bio-Rad from Lumileds, where he served as Chief Financial Officer. Mr. Daskal holds a Masters in Finance degree from City University of New York and a BB in Accounting from Tel-Aviv College of Business in Israel.

  • Business Wire22 days ago

    Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.

  • GlobeNewswire28 days ago

    Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire29 days ago

    Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"). As previously disclosed, the reason for the delay is the additional time needed by Bio-Rad to complete its year-end procedures, including its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018.

  • Business Wire2 months ago

    Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2018.

  • The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare
    American City Business Journals2 months ago

    The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare

    The typical Facebook employee makes double what the typical household in Silicon Valley makes — even as the region's household earnings rose to an all-time high last year.

  • Business Wire2 months ago

    Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S.

  • Business Wire2 months ago

    Bio-Rad to Report Fourth-Quarter and Full-Year 2018 Financial Results Thursday, February 28, 2019

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2018 on Thursday, February 28, 2019, following the close of the market. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., conference ID: 9099577. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019

    NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • This is how much Apple pays a typical employee — and how that compares to Google, Facebook, Netflix, Microsoft, Box and more
    American City Business Journals3 months ago

    This is how much Apple pays a typical employee — and how that compares to Google, Facebook, Netflix, Microsoft, Box and more

    Apple's typical employee probably makes far less than you think: $55,426 per year. For comparison, the median employee at social media giant Facebook makes more than $240,000 per year. Most likely, that median employee at Apple is not somebody writing code or designing iPhones out of a cubicle in Cupertino, but rather a worker at one of the company's retail stores.

  • Business Wire4 months ago

    Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Christine A. Tsingos has informed the company of her intention to retire as Executive Vice President and Chief Financial Officer effective April 30, 2019. Ms. Tsingos will remain in her current role through April 30 and will assist in the orderly transition to a successor. “After 16 years as CFO of Bio-Rad, Christine leaves a tremendous legacy of financial stewardship that has served the company and investors well,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer.

  • Business Wire4 months ago

    Bio-Rad to Participate at the 37th Annual J.P. Morgan Healthcare Conference on January 8

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will participate in the 37th Annual J.P.

  • Hedge Funds Are Crazy About Bio-Rad Laboratories, Inc. (BIO)
    Insider Monkey4 months ago

    Hedge Funds Are Crazy About Bio-Rad Laboratories, Inc. (BIO)

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]